Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

Market Cap	4.80B -18.2%
Revenue (ttm)	911.30M +5.2%
Net Income	218.28M -27.8%
EPS	2.75 -28.0%
Shares Out	78.31M
PE Ratio	22.28
Forward PE	n/a
Dividend	2.00 (3.28%)
Ex-Dividend Date	n/a

Volume	218,487
Average Volume	316,490
Open	60.95
Previous Close	60.90
Day's Range	60.63 - 61.33
52-Week Range	60.26 - 78.20
Beta	0.44
RSI	40.87
Earnings Date	Apr 20, 2026

About Hangzhou Alltest Biotech

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; fluorescence immunoassay tests and analyzers; urine analysis solutions, biochemistry reagents, VTM, blood glucose monitoring systems, and HB hemoglobin te...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2009
• Employees: 960
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688606

Financial Performance

In 2025, Hangzhou Alltest Biotech's revenue was 911.30 million, an increase of 5.16% compared to the previous year's 866.58 million. Earnings were 218.28 million, a decrease of -27.83%.